Q-omics provides the consensus-scored MTRES1 profile across patient tissues and cancer cell-line models. MTRES1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MTRES1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, MTRES1 RNA expression shows 17,870 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, KICH, and UVM as cancer lineages where MTRES1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTRES1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTRES1 survival associations across molecular data types. MTRES1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTRES1 RNA expression–survival associations across cancer types. High MTRES1 expression shows unfavorable associations in LIHC, KICH and HNSC, but favorable associations in PAAD, BLCA and THCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MTRES1 RNA expression.
This table summarizes MTRES1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MTRES1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTRES1 shows lower tumor expression in KICH, THCA, KIRP and KIRC and higher tumor expression in LIHC and LUSC. The KICH box plot shows higher MTRES1 RNA expression in normal versus tumor tissue (log2 FC = −0.895, t-test p < 0.001).
This table shows molecular features associated with MTRES1 in patient tissues and cancer cell lines. In patient samples, MTRES1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MTRES1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
